Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

25%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
9(75.0%)
Phase 4
2(16.7%)
Phase 3
1(8.3%)
12Total
N/A(9)
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)